Market Overview

BELLUS Health to Present at Baird 2018 Global Healthcare Conference

Share:

BELLUS Health to Present at Baird 2018 Global Healthcare Conference

Canada NewsWire

LAVAL, QC, Aug. 30, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including its lead program BLU-5937 for the treatment of chronic cough, on Thursday September 6, 2018 at 2:00 pm ET at the Baird 2018 Global Healthcare Conference in New York.

The presentation will be webcast live at http://wsw.com/webcast/baird52/blu.to/ and archived for 90 days after the event. To ensure a timely connection to the live webcast it is recommended that users register at least 15 minutes prior to the scheduled start time.

Following the event, the archived webcast and BELLUS Health's presentation will be available on the Company's website at www.bellushealth.com.

About the Conference

The Baird 2018 Global Healthcare Conference will be held at the InterContinental New York Barclay Hotel in New York on September 5 and 6, 2018. This conference brings institutional and private equity investors together with senior management from over 90 public and privately-held companies. The conference will feature companies across the following sectors: Biotechnology, Healthcare Supply Chain & Pharma Services, Healthcare Information Technology, Life Sciences & Diagnostics, Medical Technology and Facilities & Services.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company's lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies.

Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. A recent commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

SOURCE BELLUS Health Inc.

View original content: http://www.newswire.ca/en/releases/archive/August2018/30/c3208.html

View Comments and Join the Discussion!